Casdatifan(新型HIF-2α抑制剂)在健康受试者中的药代动力学、药效学与安全性
该首次人体研究在70名健康受试者中评估了口服HIF-2α抑制剂casdatifan的PK、PD与安全性,包含单次递增剂量(3-100 mg)、多次递增剂量(15-50 mg每日一次)及咪达唑仑药物相互作用部分。结果显示casdatifan暴露呈剂量比例增加,半衰期约24小时,促红细胞生成素降低41-85%,为弱CYP3A4诱导剂,安全可耐受。
要点
- Casdatifan单次3-100 mg及多次15-50 mg给药后血浆暴露呈剂量比例增加,平均半衰期约24小时。
- 单次和多次给药后观察到剂量和浓度依赖性促红细胞生成素降低41-85%,提示HIF-2α通路抑制。
- 咪达唑仑DDI部分显示casdatifan在所试剂量下为弱CYP3A4诱导剂,约30%总清除经肾清除。
核心结论
- Casdatifan在健康受试者中单次和多次给药安全且可耐受,线性PK伴随单次和多次给药后平均最大促红细胞生成素降低85%,显示良好的暴露-生物活性特征。
研究设计与样本
- 首次人体研究(NCT05117554)纳入70名健康受试者,包括双盲、随机、安慰剂对照的单次递增剂量(3-100 mg)部分、多次递增剂量(15-50 mg每日一次)部分,以及开放标签、固定序列、两周期DDI部分评估多次casdatifan对单次咪达唑仑PK的影响。
主要发现
- 健康受试者中casdatifan血浆暴露在单次3-100 mg和多次每日15-50 mg范围内呈剂量比例增加,平均半衰期约24小时,PK参数不随时间变化。
- 单次和多次给药后观察到剂量和浓度依赖性促红细胞生成素降低,范围41-85%,与外周非肿瘤性HIF-2α抑制一致。
- 咪达唑仑DDI部分结果表明casdatifan在所试剂量下为弱CYP3A4诱导剂。
- 尿液PK数据显示约30%的casdatifan总清除似通过肾清除。
临床怎么用
- 临床使用casdatifan时需关注其弱CYP3A4诱导效应及约30%肾清除比例,合并CYP3A4底物或肾功能不全患者时应评估相互作用与剂量调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Casdatifan is an orally bioavailable small-molecule hypoxia-inducible factor-2α (HIF-2α) inhibitor currently in development for treating patients with clear cell renal cell carcinomas. The aim of this study was to characterize the pharmacokinetics (PK), pharmacodynamics and safety of casdatifan in healthy participants. METHODS: This first-in-human study (NCT05117554) investigating casdatifan in 70 healthy participants consisted of 3 parts: a double-blind, randomized, placebo-controlled single ascending dose (3-100 mg) part; a multiple ascending dose (15-50 mg once daily) part; and an open-label, fixed sequence, 2-period, drug-drug interaction part to evaluate the effect of multiple doses of casdatifan on the single-dose PK of midazolam. RESULTS: In healthy participants, casdatifan plasma exposure increased dose proportionally over a single dose of 3-100 mg and multiple daily doses of 15-50 mg. The mean half-life of casdatifan was approximately 24 h, and PK parameters did not change over time. Dose- and concentration-dependent reduction, ranging from 41 to 85%, in erythropoietin (a pharmacodynamic biomarker for peripheral, nontumour, HIF-2α inhibition) was observed after single and multiple doses, consistent with HIF-2α pathway inhibition. Results from the midazolam drug-drug interaction part indicated that casdatifan was a weak CYP3A4 inducer at the tested dose. Urine PK data showed that approximately 30% of the overall casdatifan clearance appears to be via renal clearance. CONCLUSIONS: Casdatifan, after single and multiple dosing in healthy participants, was safe and tolerable. Linear PK was associated with a mean maximum erythropoietin reduction of 85% following a single dose and multiple doses of casdatifan, demonstrating a promising exposure-biological activity profile.
引用
- Ghasemi M, Kim JY, Seitz L, et al. Pharmacokinetics, pharmacodynamics and safety of casdatifan, a novel hypoxia-inducible factor-2α inhibitor, in healthy participants. Br J Clin Pharmacol. 2025. PMID: 40717339. doi:10.1002/bcp.70169
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。